Biohit Oyj Correction Biohit takes the threat of the Corona virus extremely seriously. Based on the development of the Corona virus situation and the policy of the Finnish Government Biohit has decided to convene the Annual General Meeting at a later stage, when the Corona virus does not cause any risks for the health of the participants. Helsinki, 27 March 2020 Biohit Oyj Board of Directors Additional information:CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi (https://www.globenewswire.com/Tracker?data=PwLdjOY0 0JDDDIZWV3-Lmeo6BH0fdQLM9yb1zBCDsvs -uICjtCkBIy2tb1HTruxXGgM0sytMst0SnnB9y_0blhIlfD1kTvAvK_YzHjWMSwTdVI9OEcvWOK6Hervm ezWD) www.biohithealthcare.com (https://www.globenewswire.com/Tracker?data=c5rWyQltbzVN ETEAzPUZ5WLkdGhFEQ1oTBo35iEHNX-lvCr-94PYSU_QxddYHsnlfS_ChSNOY -aUgD_x7sYeKlJobL86Vz2jeJMdEZy73CA3pSWmapSEFnK8HcdUe6Ek) Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com (https://www.globenewswire.com/Tracker?data=c5rWy QltbzVNETEAzPUZ5WLkdGhFEQ1oTBo35iEHNX8xhFJ8UXxKcBfwNUj1oaJLkJWDIfhT0_qN_43uOPrHsI IWy25pE_7iX8aTY-nisGmlggNS87UH1ViJkQ-0ezca)